{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:22Z","timestamp":1787032762702,"version":"build-2736575974"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,26]]},"DOI":"10.7759\/cureus.34245","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T21:37:26Z","timestamp":1674769046000},"source":"Crossref","is-referenced-by-count":11,"title":["Nanotechnology in Lung Cancer Therapeutics: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Vaibhav","family":"Koutu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak K","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Kharade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh K","family":"Pasricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"The top 10 causes of death. (2020). Accessed. May 5, 2022: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death#:~:text=The%20top%20global%20causes%20of,...."},{"key":"ref2","unstructured":"Cancer. (2022). Accessed. May 5, 2022: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","author":"Tran S","year":"2017","unstructured":"Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017, 6:44. 10.1186\/s40169-017-0175-0","journal-title":"Clin Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40820-021-00630-6","article-title":"Bio-nanocarriers for lung cancer management: befriending the barriers","volume":"13","author":"Rawal S","year":"2021","unstructured":"Rawal S, Patel M. Bio-nanocarriers for lung cancer management: befriending the barriers. Nanomicro Lett. 2021, 13:142. 10.1007\/s40820-021-00630-6","journal-title":"Nanomicro Lett"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/nano11071727","article-title":"From nanoparticles to cancer nanomedicine: old problems with new solutions","volume":"11","author":"Chiang CL","year":"2021","unstructured":"Chiang CL, Cheng MH, Lin CH. From nanoparticles to cancer nanomedicine: old problems with new solutions. Nanomaterials (Basel). 2021, 11:1727. 10.3390\/nano11071727","journal-title":"Nanomaterials (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.02.010","article-title":"Nanotechnology in the diagnosis and treatment of lung cancer","volume":"198","author":"Cryer AM","year":"2019","unstructured":"Cryer AM, Thorley AJ. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol Ther. 2019, 198:189-205. 10.1016\/j.pharmthera.2019.02.010","journal-title":"Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao Y","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, et al.. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020, 7:193. 10.3389\/fmolb.2020.00193","journal-title":"Front Mol Biosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15226\/2374-6866\/1\/2\/00109","article-title":"Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development","volume":"1","author":"Pillai G","year":"2014","unstructured":"Pillai G. Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ Pharmacy & Pharmaceutical Sciences. 2014, 1:1-13. 10.15226\/2374-6866\/1\/2\/00109","journal-title":"SOJ Pharmacy & Pharmaceutical Sciences"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107 S","year":"2022","unstructured":"\u0110or\u0111evi\u0107 S, Gonzalez MM, Conejos-S\u00e1nchez I, et al.. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022, 12:500-25. 10.1007\/s13346-021-01024-2","journal-title":"Drug Deliv Transl Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01369","article-title":"Recalcitrant issues and new frontiers in nano-pharmacology","volume":"10","author":"Bhardwaj V","year":"2019","unstructured":"Bhardwaj V, Kaushik A, Khatib ZM, Nair M, McGoron AJ. Recalcitrant issues and new frontiers in nano-pharmacology. Front Pharmacol. 2019, 10:1369. 10.3389\/fphar.2019.01369","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111972","article-title":"Smart nanotherapeutics and lung cancer","volume":"13","author":"Doroudian M","year":"2021","unstructured":"Doroudian M, Azhdari MH, Goodarzi N, O'Sullivan D, Donnelly SC. Smart nanotherapeutics and lung cancer. Pharmaceutics. 2021, 13:1972. 10.3390\/pharmaceutics13111972","journal-title":"Pharmaceutics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen Z","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014, 14:535-46. 10.1038\/nrc3775","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto","volume":"37","author":"Untch M","year":"2019","unstructured":"Untch M, Jackisch C, Schneeweiss A, et al.. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto. J Clin Oncol. 2019, 37:2226-34. 10.1200\/JCO.18.01842","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.09.007","article-title":"Nanoparticle albumin-bound paclitaxel plus carboplatin induction followed by nanoparticle albumin-bound paclitaxel maintenance in squamous non-small-cell lung cancer (ABOUND.sqm): a phase III randomized clinical trial","volume":"22","author":"Spigel DR","year":"2021","unstructured":"Spigel DR, Jotte RM, Aix SP, et al.. Nanoparticle albumin-bound paclitaxel plus carboplatin induction followed by nanoparticle albumin-bound paclitaxel maintenance in squamous non-small-cell lung cancer (ABOUND.sqm): a phase III randomized clinical trial. Clin Lung Cancer. 2021, 22:6-15.e4. 10.1016\/j.cllc.2020.09.007","journal-title":"Clin Lung Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.479","article-title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial","volume":"32","author":"Shi M","year":"2021","unstructured":"Shi M, Gu A, Tu H, et al.. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Ann Oncol. 2021, 32:85-96. 10.1016\/j.annonc.2020.10.479","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32573","article-title":"Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy","volume":"126","author":"Weiss JM","year":"2020","unstructured":"Weiss JM, Pennell N, Deal AM, et al.. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. Cancer. 2020, 126:1060-7. 10.1002\/cncr.32573","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid P","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al.. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018, 379:2108-21. 10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski MA","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, et al.. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012, 30:2055-62. 10.1200\/JCO.2011.39.5848","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares L","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al.. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018, 379:2040-51. 10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.027","article-title":"Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC","volume":"16","author":"Yoneshima Y","year":"2021","unstructured":"Yoneshima Y, Morita S, Ando M, et al.. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol. 2021, 16:1523-32. 10.1016\/j.jtho.2021.03.027","journal-title":"J Thorac Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4605-1","article-title":"Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience","volume":"18","author":"Glassman DC","year":"2018","unstructured":"Glassman DC, Palmaira RL, Covington CM, et al.. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer. 2018, 18:693. 10.1186\/s12885-018-4605-1","journal-title":"BMC Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz Y","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012, 160:117-34. 10.1016\/j.jconrel.2012.03.020","journal-title":"J Control Release"},{"key":"ref23","unstructured":"Center for Drug Evaluation and Research. application number 40263. (1999). Accessed: July 8, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/anda\/99\/40263_Methotrexate_Approv.pdf."},{"key":"ref24","unstructured":"Drugs approved for lung cancer. (2022). Accessed. July 8, 2022: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/lung."},{"key":"ref25","unstructured":"Center for Drug Evaluation and Research. application number: 202317Orig1s000. (2013). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/202317Orig1s000Approv.pdf."},{"key":"ref26","unstructured":"Center for Drug Evaluation and Research. application number: 20-981. (2007). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/020981s000_Approv.pdf."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7439.1000164","article-title":"Paclitaxel nano-delivery systems: a comprehensive review","volume":"4","author":"Ma P","year":"2013","unstructured":"Ma P, Mumper RJ. Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol. 2013, 4:1000164. 10.4172\/2157-7439.1000164","journal-title":"J Nanomed Nanotechnol"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Center for Drug Evaluation and Research. application number: 20-452. (2003). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/20-452.pdf_Paraplatin_Approv.pdf.","DOI":"10.1046\/j.1365-2230.2003.01285_5.x"},{"key":"ref29","unstructured":"FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR\/ALK aberrations. (2019). Accessed. July 8, 2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-nab-paclitaxel-and-carboplat...."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian D","year":"2016","unstructured":"Kazandjian D, Suzman DL, Blumenthal G, et al.. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016, 21:634-42. 10.1634\/theoncologist.2015-0507","journal-title":"Oncologist"},{"key":"ref31","article-title":"Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement","volume":"33","author":"Pircher A","year":"2013","unstructured":"Pircher A, Wasle IK, Mian M, et al.. Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement. Anticancer Res. 2013, 33:3831-6.","journal-title":"Anticancer Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0221","article-title":"U.S. Food and Drug Administration approval summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy","volume":"20","author":"Larkins E","year":"2015","unstructured":"Larkins E, Scepura B, Blumenthal GM, et al.. U.S. Food and Drug Administration approval summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy. Oncologist. 2015, 20:1320-5. 10.1634\/theoncologist.2015-0221","journal-title":"Oncologist"},{"key":"ref33","unstructured":"FDA approves first targeted therapy to treat aggressive form of lung cancer. (2020). Accessed. July 12, 2022: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-ca...."},{"key":"ref34","unstructured":"Center for Drug Evaluation and Research. application number: 200795Orig1s000. (2011). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/200795Orig1s000Approv.pdf."},{"key":"ref35","unstructured":"Center for Drug Evaluation and Research. application number: NDA20-262-\/S-024. (1998). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20262s024_Taxol_appltr.pdf."},{"key":"ref36","unstructured":"Department of Health & Human Services. NDA 21-462\/S-015. (2008). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2008\/021462s015ltr.pdf."},{"key":"ref37","unstructured":"Department of Health & Human Services. NDA 20388\/S-27. (1994). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/020388Orig1s027ltr.pdf."},{"key":"ref38","unstructured":"Center for Drug Evaluation and Research. application number: 22-334. (2009). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022334s000_Approv.pdf."},{"key":"ref39","unstructured":"Center for Drug Evaluation and Research. application number: 201292Orig1s000. (2013). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/201292Orig1s000Approv.pdf."},{"key":"ref40","unstructured":"Center for Drug Evaluation and Research. application number: 208434Orig1s000. (2015). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/208434Orig1s000Approv.pdf."},{"key":"ref41","unstructured":"FDA approves brigatinib for ALK-positive metastatic NSCLC. (2020). Accessed. July 13, 2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brigatinib-alk-positive-metastatic-nsclc."},{"key":"ref42","unstructured":"FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC. (2017). Accessed. July 12, 2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-broadens-ceritinib-indication-previously-untreated...."},{"key":"ref43","unstructured":"FDA approves crizotinib for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma. (2021). Accessed. July 12, 2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizotinib-children-and-young-adults-rela...."},{"key":"ref44","unstructured":"Center for Drug Evaluation and Research. application number: 211288Orig1s000. (2018). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211288Orig1s000Approv.pdf."},{"key":"ref45","unstructured":"Center for Drug Evaluation and Research. application number 212725Orig1s000, 212726Orig1s000. (2019). Accessed: July 28, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212725Orig1s000,%20212726Orig1s000Approv.pdf."},{"key":"ref46","unstructured":"Center for Drug Evaluation and Research. application number: 21-743. (2004). Accessed: July 29, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-743_Tarceva_approv.PDF."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0257","article-title":"Approval summary: erlotinib maintenance therapy of advanced\/metastatic non-small cell lung cancer (NSCLC)","volume":"15","author":"Cohen MH","year":"2010","unstructured":"Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, Sridhara R, Pazdur R. Approval summary: erlotinib maintenance therapy of advanced\/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010, 15:1344-51. 10.1634\/theoncologist.2010-0257","journal-title":"Oncologist"},{"key":"ref48","unstructured":"Center for Drug Evaluation and Research. application number: 21-399. (2003). Accessed: July 29, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-399_IRESSA_Approv.pdf."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer","volume":"22","author":"Kazandjian D","year":"2016","unstructured":"Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 2016, 22:1307-12. 10.1158\/1078-0432.CCR-15-2266","journal-title":"Clin Cancer Res"},{"key":"ref50","unstructured":"FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations. (2020). Accessed. July 29, 2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-adjuvant-therapy-non-small-ce...."},{"key":"ref51","unstructured":"Osimertinib mesylate. (2015). Accessed. July 13, 2022: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Osimertinib-mesylate."},{"key":"ref52","unstructured":"Department of Health & Human Services. NDA 204114. (2013). Accessed: July 29, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2013\/204114Orig1s000ltr.pdf."},{"key":"ref53","unstructured":"Center for Drug Evaluation and Research. application number: 761041Orig1s000. (2016). Accessed: July 29, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/761041Orig1s000Approv.pdf."},{"key":"ref54","unstructured":"Center for Drug Evaluation and Research. application number: 125514Orig1s000. (2014). Accessed: July 29, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125514Orig1s000Approv.pdf."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf L","year":"2017","unstructured":"Pai-Scherf L, Blumenthal GM, Li H, et al.. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist. 2017, 22:1392-9. 10.1634\/theoncologist.2017-0078","journal-title":"Oncologist"},{"key":"ref56","unstructured":"Center for Drug Evaluation and Research. application number: 125527Orig1s000. (2015). Accessed: July 29, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125527Orig1s000Approv.pdf."},{"key":"ref57","unstructured":"Avastin FDA approval history. (2004). Accessed. July 13, 2022: https:\/\/www.drugs.com\/history\/avastin.html."},{"key":"ref58","unstructured":"Center for Drug Evaluation and Research. application number: STN-125080\/0. (2004). Accessed: July 13, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/STN-125085_Avastin_Approv.pdf."},{"key":"ref59","unstructured":"Center for Drug Evaluation and Research. application number: 761069Orig1s000. (2017). Accessed: July 13, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761069Orig1s000Approv.pdf."},{"key":"ref60","unstructured":"Center for Drug Evaluation and Research. application number: 125547Orig1s000. (2015). Accessed: July 13, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125547Orig1s000Approv.pdf."},{"key":"ref61","unstructured":"Center for Drug Evaluation and Research. application number: 125477Orig1s000. (2014). Accessed: July 13, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125477Orig1s000Approv.pdf."},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-46143-6.00007-5","article-title":"Nanofibrous and nanoparticle materials as drug-delivery systems","author":"Zamani F","year":"2017","unstructured":"Zamani F, Jahanmard F, Ghasemkhah F, et al.. Nanofibrous and nanoparticle materials as drug-delivery systems. Nanostructures for Drug Delivery. Andronescu E, Grumezescu AM (ed): Elsevier, Amsterdam, Netherlands; 2017. 239-70. 10.1016\/B978-0-323-46143-6.00007-5"},{"key":"ref63","article-title":"Novel Drug Delivery Systems","author":"Tripathi DK","year":"2020","unstructured":"Tripathi DK, Alexander A. Novel Drug Delivery Systems. PharmaMed Press, 2020."},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-28030-6_2","article-title":"Unique properties of nanomaterials","author":"Murty BS","year":"2013","unstructured":"Murty BS, Shankar P, Raj B, Murday J. Unique properties of nanomaterials. Textbook of Nanoscience and Nanotechnology. Springer International Publishing, Berlin, Heidelberg; 2013. 29:29-65. 10.1007\/978-3-642-28030-6_2"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s596","article-title":"Drug delivery and nanoparticles:applications and hazards","volume":"3","author":"De Jong WH","year":"2008","unstructured":"De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008, 3:133-49. 10.2147\/ijn.s596","journal-title":"Int J Nanomedicine"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2011.12.033","article-title":"Protein based nanoparticles as platforms for aspirin delivery for ophthalmologic applications","volume":"93","author":"Das S","year":"2012","unstructured":"Das S, Bellare JR, Banerjee R. Protein based nanoparticles as platforms for aspirin delivery for ophthalmologic applications. Colloids Surf B Biointerfaces. 2012, 93:161-8. 10.1016\/j.colsurfb.2011.12.033","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.12989\/anr.2019.7.4.231","article-title":"Apoptosis and inhibition of human epithelial cancer cells by ZnO nanoparticles synthesized using plant extract","volume":"7","author":"Koutu V","year":"2019","unstructured":"Koutu V, Rajawat S, Shastri L, Malik MM. Apoptosis and inhibition of human epithelial cancer cells by ZnO nanoparticles synthesized using plant extract. Adv Nano Res. 2019, 7:231-9. 10.12989\/anr.2019.7.4.231","journal-title":"Adv Nano Res"},{"key":"ref68","article-title":"Controlling drug delivery","author":"Perrie Y","year":"2009","unstructured":"Perrie Y, Rades T. Controlling drug delivery. Pharmaceutics: Drug Delivery and Targeting. Pharmaceutical Press, London; 2009. 1:1-24."},{"key":"ref69","article-title":"Sustained release oral drug delivery system: a concise review","volume":"54","author":"Mishra S","year":"2019","unstructured":"Mishra S. Sustained release oral drug delivery system: a concise review. Int J Pharm Sci Rev Res. 2019, 54:5-15.","journal-title":"Int J Pharm Sci Rev Res"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0040-2","article-title":"Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement","volume":"52","author":"Stuurman FE","year":"2013","unstructured":"Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet. 2013, 52:399-414. 10.1007\/s40262-013-0040-2","journal-title":"Clin Pharmacokinet"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108177","article-title":"Anti-cancer activity of sustained release capsaicin formulations","volume":"238","author":"Merritt JC","year":"2022","unstructured":"Merritt JC, Richbart SD, Moles EG, et al.. Anti-cancer activity of sustained release capsaicin formulations. Pharmacol Ther. 2022, 238:108177. 10.1016\/j.pharmthera.2022.108177","journal-title":"Pharmacol Ther"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.apt.2018.05.012","article-title":"Study the effect of dip in reaction temperature on thermal and electrical properties of ZnO nanoparticles","volume":"29","author":"Koutu V","year":"2018","unstructured":"Koutu V, Subohi O, Shastri L, Malik MM. Study the effect of dip in reaction temperature on thermal and electrical properties of ZnO nanoparticles. Adv Powder Technol. 2018, 29:2061-9. 10.1016\/j.apt.2018.05.012","journal-title":"Adv Powder Technol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.12980\/APJTB.4.2014C980","article-title":"Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine","volume":"4","author":"Gunasekaran T","year":"2014","unstructured":"Gunasekaran T, Haile T, Nigusse T, Dhanaraju MD. Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine. Asian Pac J Trop Biomed. 2014, 4:S1-7. 10.12980\/APJTB.4.2014C980","journal-title":"Asian Pac J Trop Biomed"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi J","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017, 17:20-37. 10.1038\/nrc.2016.108","journal-title":"Nat Rev Cancer"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.matpr.2020.05.380","article-title":"Nanomaterials in medicine - an overview","volume":"37","author":"Damodharan J","year":"2021","unstructured":"Damodharan J. Nanomaterials in medicine - an overview. Mater Today: Proc. 2021, 37:383-5. 10.1016\/j.matpr.2020.05.380","journal-title":"Mater Today: Proc"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-676X.2015.08.05","article-title":"Emerging chemotherapy agents in lung cancer: nanoparticles therapeutics for non-small cell lung cancer","volume":"4","author":"In GK","year":"2015","unstructured":"In GK, Nieva J. Emerging chemotherapy agents in lung cancer: nanoparticles therapeutics for non-small cell lung cancer. Transl Cancer Res. 2015, 4:340-55. 10.3978\/j.issn.2218-676X.2015.08.05","journal-title":"Transl Cancer Res"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell MJ","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021, 20:101-24. 10.1038\/s41573-020-0090-8","journal-title":"Nat Rev Drug Discov"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/113832-nanotechnology-in-lung-cancer-therapeutics-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:57:58Z","timestamp":1707490678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/113832-nanotechnology-in-lung-cancer-therapeutics-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":77,"URL":"https:\/\/doi.org\/10.7759\/cureus.34245","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}